Elastrin Therapeutics
Greenville, US · Founded 2017 · Delaware corporation
Biotech
Founders & leadership
NV
Naren VyavahareExecutive Officer, Director
MB
Matthias BreugelmansExecutive Officer, Director
PB
Patrick BurgermeisterDirector
Reported raises · per SEC filings
Form D private placements▶$500KraisedMar 2025 · 1 investors · BiotechnologyRule 506(b)
▶$500KraisedMar 2025 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Naren VyavahareExecutive Officer, Director
- Offering amount
- $500K
- Amount sold
- $500K
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedNov 2023 · 2 investors · BiotechnologyRule 506(b)
▶$2MraisedNov 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patrick BurgermeisterDirector
- Klaus-Dieter LangnerDirector
- Naren VyavahareExecutive Officer, Director
- Matthias BreugelmansExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.8MraisedNov 2023 · 3 investors · BiotechnologyRule 506(b)
▶$4.8MraisedNov 2023 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthias BreugelmansExecutive Officer, Director
- Naren VyavahareExecutive Officer, Director
- Klaus-Dieter LangnerDirector
- Patrick BurgermeisterDirector
- Offering amount
- $4.8M
- Amount sold
- $4.8M
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.5MraisedMar 2022 · 1 investors · BiotechnologyRule 506(b)
▶$2.5MraisedMar 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patrick BurgermeisterDirector
- Naren VyavahareExecutive Officer, Director
- Matthias BreugelmansExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- Finders' fees
- $180.8K
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$3.6MraisedMar 2022 · 3 investors · BiotechnologyRule 506(b)
▶$3.6MraisedMar 2022 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthias BreugelmansExecutive Officer, Director
- Naren VyavahareExecutive Officer, Director
- Patrick BurgermeisterDirector
- Offering amount
- $10M
- Amount sold
- $3.6M
- First sale
- Mar 2022
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2019 | $284K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.